Nucleic Acid, Nucleoside, or Nucleotide – Page 10

GSK Partners with Flagship Pioneering to Develop 10 Novel Medicines and Vaccines

11 months ago talkbio0Tagged bioplatform companies, Drug Discovery, Flagship, Immunology, Partnership, Pfizer, Pioneering, Respiration Disorders, RNA, Messenger, SmithKline Beecham, Vaccines

GSK, Flagship Pioneering, drug discovery, vaccines, respiratory disease, immunology, bioplatform companies, mRNA vaccines, Pfizer, biotech partnership

Pfizer and Sangamo’s Gene Therapy Shows Superiority Over Prophylaxis in Hemophilia A Study

11 months ago talkbio0Tagged factor VIII, gene therapy, Giroctocogene fitelparvovec, Hemophilia A, Hemorrhage, Pfizer, prevention & control, Rating (action), Sangamo

Pfizer, Sangamo, gene therapy, hemophilia A, prophylaxis, giroctocogene fitelparvovec, bleeding rate, Factor VIII

FDA Issues Warning Letter to Indian CDMO Brassica for Data Falsification and Poor Hygiene Practices

11 months ago talkbio0Tagged Asian Indian, Cautionary Warning, CDMO, Cyclic GMP, Data Falsification, Indian, Letter [Publication Type], Pharma, United States Food and Drug Administration, Violations

FDA, Warning Letter, Brassica Pharma, Data Falsification, Poor Hygiene, Indian CDMO, CGMP Violations

Agilent Technologies Acquires Biovectra for $925 Million to Enhance Biologics and CRISPR Capabilities

11 months ago talkbio0Tagged Acquisition (action), Agilent Technologies, Biological Factors, Biovectra, CDMO, Clustered Regularly Interspaced Short Palindromic Repeats, Contract agreement, Manufacturing Organization

Agilent Technologies, Biovectra, Acquisition, Biologics, CRISPR, Contract Development and Manufacturing Organization (CDMO)

Ionis Advances to Phase 3 Trial for Angelman Syndrome Treatment ION582

11 months ago talkbio0Tagged Angelman Syndrome, Antisense, Biogen, Dosage Forms, ION582, Ionis Pharmaceuticals, neurological conditions, Oligonucleotides, Phase 3 trial, Ultragenyx

Ionis Pharmaceuticals, Angelman syndrome, ION582, Phase 3 trial, antisense oligonucleotides, neurological conditions, rare diseases, Biogen, Ultragenyx Pharmaceutical